Navigation Links
Cardiva Medical, Inc. Announces the Departure of its President and his Appointment as CEO of Innovative Energy, Inc.
Date:10/14/2009

MOUNTAIN VIEW, Calif. and ST. LOUIS, Oct. 14 /PRNewswire/ -- Cardiva Medical, Inc. announces today that its President, Glenn Foy, will depart the organization to assume the position of Chief Executive Officer at Innovative Energy, Inc., an alternative energy company.

Augustine Lien, Founder and CEO of Cardiva Medical stated, "I would like to thank Glenn for his contributions to Cardiva over the past six years. During his tenure as President, we have transformed Cardiva from an early stage start-up to a commercial medical device company with a world-class product development, manufacturing and sales organization and significant revenues." Mr. Lien added, "With our recent successful launch of Cardiva Catalyst(TM) III, we are well positioned to lead the large vessel closure market and I wish Glenn the best as he assumes his new role at Innovative Energy."

"We are thrilled that Glenn will be joining the executive team at Innovative Energy," said Andy Schlote, Founder, Chairman and CTO of Innovative Energy, Inc. "His broad range of experience and his leadership ability make him the ideal choice to transition Innovative Energy from a product development company to a commercial frontrunner in the renewable, clean energy space." Mr. Schlote continued, "As we prepare to deliver on our first power delivery contract, Glenn's long track record of commercial successes will be a significant asset."

"I appreciate the opportunity I've been given at Cardiva and am proud of our many accomplishments as a team," added Glenn Foy. "I am very excited about my new role at Innovative Energy. They have developed truly transformational technology that will allow municipalities to locally generate renewable, clean energy at a lower cost than purchasing electricity derived from conventional fossil fuels." Foy continued, "Limiting fossil fuels and their enormous environmental impact in electricity generation is a global initiative. Innovative Energy has developed the technology that will allow it to lead in this effort."

About Cardiva Medical, Inc.

Cardiva Medical, Inc., a privately held medical device company that designs, develops and commercializes endovascular products which help the body heal itself. In 2005, Cardiva launched its first product into the vessel closure market, the Boomerang® Wire System, which demonstrated unsurpassed ease-of-use and safety. In January 2008, Cardiva launched the Cardiva Catalyst II, which incorporates hemostatic agents to accelerate the body's own coagulation pathway; quickly facilitating hemostasis at the arteriotomy site, preserving the artery and leaving absolutely nothing behind in the patient. In May 2009, Cardiva launched its latest vessel closure system, the Cardiva Catalyst III device, which is indicated for use in heparinized patients undergoing diagnostic and/or interventional femoral artery catheterization procedures using 5F, 6F, or 7F introducer sheaths. In 2006, Cardiva was presented the prestigious Frost & Sullivan Award which recognizes entrepreneurial excellence in the U.S. angioplasty and vascular closure devices market. For additional information about Cardiva, please visit our website at www.cardivamedical.com.

About Innovative Energy, Inc.

Innovative Energy, Inc., a privately held energy company, located in St. Louis, Missouri that designs, develops, and produces power plants capable of generating renewable, clean energy locally that cost less than traditional fossil fuels. Founded in 2001, the Company has had numerous patents issued in the US and worldwide on its technology and expects to launch its technology into the United States early in 2010. For additional information, please visit our website at www.innovativeenergyinc.com.

    Media Contact for Cardiva Medical Inc.:
    Mac Farnsworth, VP and CFO
    Cardiva Medical, Inc.
    Phone: 408.470.7118
    Fax: 408.212.9889
    mac_farnsworth@cardivamedical.com

    Media Contact for Innovative Energy Inc.:
    Andy Schlote, Founder, Chairman and CTO
    Innovative Energy, Inc.
    Phone: 636.600.1230
    Fax: 636.600.1231
    aschlote@iei-us.com

Cardiva Catalyst, Boomerang and Boomerang Catalyst are trademarks/registered trademarks of Cardiva Medical, Inc.

SOURCE Cardiva Medical, Inc.


'/>"/>
SOURCE Cardiva Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Prescient Medical, Inc. Acquires New Technology to Detect Inflammation in Coronary Blood Vessels
2. Prescient Medical, Inc. Achieves Successful Clinical Debut of vProtect(TM) Luminal Shield
3. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
4. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
5. New Study Shows that Prebiotics, as Used by Jackson GI Medical, Increases Lifespan by 33%
6. Luminous Medical, Inc. Secures Exclusive Rights to Glucose Sensor for Its Automated Glucose Monitor
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing ... this week,s Orlando Dermatology Aesthetic & Clinical (ODAC) Conference, which ... inflammation. The data will be shared in a ... at ODAC, which is being held Jan. 13-16 in ... ...
(Date:1/12/2017)...   TyrNovo , s NT219 drug candidate ... cancer drug resistance and would be ... NT219 is a novel proprietary ... ( IRS1/2 and STAT3) highly involved in ... .   NT219 has demonstrated ...
(Date:1/12/2017)... -- "Global Lung Cancer Vaccine Market & Pipeline ... trends in the global lung cancer vaccine market. ... available in the market. This report analyzes the ... in clinical pipeline and gives comprehensive clinical insight ... the lung cancer vaccines. Currently there are 9 ...
Breaking Medicine Technology:
(Date:1/13/2017)... ... January 13, 2017 , ... The 18th European Congress: Perspectives in ... March 3-4, 2017. This Congress is expertly designed to meet the educational needs ... with lung cancer. , Chaired by Dr. Giorgio V. Scagliotti, Professor of Oncology at ...
(Date:1/13/2017)... ... ... inventor from Pahrump, Nev., used an unsavory medical experience to think of a way to ... urine bag for a half year due to lazy bladder," he said. "Keeping these things ... better way to do this." , He then designed and created a prototype of the ...
(Date:1/13/2017)... , ... January 13, 2017 , ... Friday, January 13 ... of the game room, increasing the size of the location to 90,000 square feet. ... 8-hole mini golf course that takes customers on an educational tour of the historic ...
(Date:1/13/2017)... ... January 13, 2017 , ... As the nation watches this month’s transition ... colleges and schools of education across the country is urging a fundamental reconsideration of ... Principles released today, 175 deans sounded the alarm: “Our children suffer when we deny ...
(Date:1/13/2017)... ... January 13, 2017 , ... One way to obtain a green card is ... can show their work is in the national interest. There are two significant advantages ... be sponsored by an employer; and 2) the submission is made directly to the ...
Breaking Medicine News(10 mins):